Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Neoplasm Metastasis 3Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × STA 9090 × Clear all
NCT01579994 2020-12-30

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

NCT00687934 2014-09-18

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Synta Pharmaceuticals Corp.

Phase 1 Completed
53 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00688116 2014-09-18

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Synta Pharmaceuticals Corp.

Phase 1 Unknown
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡